Life sciences news
-
Annals of the Rheumatic Diseases publishes results from two bimekizumab Phase 3 studies in axial spondyloarthritis
Wednesday January 18th 2023
Read more
-
Oxurion announces the continuation of KALAHARI Phase 2, Part B Study in diabetic macular edema following interim analysis
Friday December 16th 2022
Read more
-
UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa
Friday December 9th 2022
Read more
-
Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023
Monday November 21st 2022
Read more
-
Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia
Tuesday November 15th 2022
Read more
-
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
Tuesday November 15th 2022
Read more
-
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
Tuesday October 25th 2022
Read more
-
Mithra announces positive preclinical data demonstrating Estetrol’s efficacy in wound healing
Wednesday October 12th 2022
Read more
-
Become a flanders.bio member
Your news here?
-
Indigo Diabetes announces first participant enrolled in the SHINE clinical trial
Thursday September 29th 2022
Read more
-
reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration
Wednesday August 31st 2022
Read more
-
Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial
Monday August 1st 2022
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
